



Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 8 (2017) 111-126

Cerebrospinal Fluid Biomarkers

Consensus guidelines for lumbar puncture in patients with neurological diseases

Sebastiaan Engelborghs^{a,b,1}, Ellis Niemantsverdriet^{a,1}, Hanne Struyfs^a, Kaj Blennow^c,

Raf Brouns^d, Manuel Comabella^e, Irena Dujmovic^f, Wiesje van der Flier^g, Lutz Frölich^h,

Daniela Galimbertiⁱ, Sharmilee Gnanapavan^j, Bernhard Hemmer^{k,1}, Erik Hoff^m, Jakub Hort^{n,o},

Ellen Iacobaeus^p, Martin Ingelsson^q, Frank Jan de Jong^r, Michael Jonsson^s, Michael Khalil^t,

Jens Kuhle^u, Alberto Lleó^{v,w}, Alexandre de Mendonça^x, José Luis Molinuevo^y, Guy Nagels^{d,z,aa}

Claire Paquet^{bb}, Lucilla Parnetti^{cc}, Gerwin Roks^{dd}, Pedro Rosa-Neto^{ee,ff}, Philip Scheltens^g,

Constance Skårsgard^{gg}, Erik Stomrud^{hh}, Hayrettin Tumaniⁱⁱ, Pieter Jelle Visser^{jj,kk}

Anders Wallin^s, Bengt Winblad¹¹, Henrik Zetterberg^{c,mm}, Flora Duits^g, Charlotte E. Teunissen^{jj,*}

^aReference Center for Biological Markers of Dementia (BIODEM), Department of Biomedical Sciences, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium

^bDepartment of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium

^cClinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden

^dDepartment of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Brussels, Belgium ^eServei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

^fClinic of Neurology, Clinical Centre of Serbia, Department of Neurology, Faculty of Medicine, University of Belgrade School of Medicine, Belgrade, Serbia ^gAlzheimer center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

^hDepartment of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty, Mannheim/Heidelberg University, Mannheim, Germany

ⁱNeurology Unit, Department of Pathophysiology and Transplantation, University of Milan, Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy

^jDepartment of Neuroscience and Trauma, Blizard Institute, Queen Mary University of London, London, United Kingdom

^kDepartment of Neurology, Technische Universität München, Munich, Germany

¹Munich Cluster for Systems Neurology (SyNergy), Munich, Germany

^mDepartment of Neurology, Atrium Medisch Centrum Parkstad, Heerlen, The Netherlands

ⁿMemory Disorders Clinic, Department of Neurology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech

Republic

^oInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic

^pDepartment of Clinical Neuroscience, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

^qDepartment of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

^rDepartment of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands

^sMemory Clinic, Department of Neuropsychiatry, Sahlgrenska University Hospital, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University

of Gothenburg, Mölndal, Sweden

^tDepartment of Neurology, Medical University Graz, Graz, Austria

^uDepartment of Neurology, University Hospital Basel, Basel, Switzerland

^vMemory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

^wCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Madrid, Spain

^xLaboratory of Neurosciences, Department of Molecular Medicine and Faculty of Medicine, University of Lisbon, Lisbon, Portugal

^yAlzheimer's disease and other cognitive disorders unit, Neurology Service, Hospital Clinic i Universitari, IDIBAPS, Barcelona, Spain

^zFaculté de Psychologie et des sciences de l'éducation, UMons, Mons, Belgium

^{aa}National MS Center Melsbroek, Brussels, Belgium

^{bb}Research Memory Center Lariboisière Hospital University Paris Diderot INSERMU942, Paris, France

¹Joint first authors.

*Corresponding author. Tel.: +31-20-4443680; Fax: +31-20-4443895.

E-mail address: c.teunissen@vumc.nl

http://dx.doi.org/10.1016/j.dadm.2017.04.007

2352-8729/ © 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

^{cc}Section of Neurology, Centre for Memory Disturbances, Department of Medicine, University of Perugia, Perugia, Italy

^{dd}Department of Neurology, St Elisabeth Ziekenhuis, Tilburg, The Netherlands

ee Departments of Neurology & Neurosurgery and Psychiatry, McGill Centre for Studies in Aging, Douglas Hospital Research Center, McGill University,

Montreal, Canada

^{ff}Departments of Psychiatry, McGill Centre for Studies in Aging, Douglas Hospital Research Center, McGill University, Montreal, Canada ^{gg}Department of Geriatrics, Kalmar County Hospital, Kalmar, Sweden

^{hh}Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden

ⁱⁱCSF Laboratory and Multiple Sclerosis Outpatient Unit, Department of Neurology, University of Ulm, Ulm, Germany

^{jj}Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands

^{kk}Alzheimer Centre Limburg, School for Mental Health and Neuroscience, Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands

¹¹Karolinska Institutet, Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division for Neurogeriatrics, Huddinge,

Sweden

mmUCL Institute of Neurology, Department of Molecular Neuroscience, London, United Kingdom

Abstract

Introduction: Cerebrospinal fluid collection by lumbar puncture (LP) is performed in the diagnostic workup of several neurological brain diseases. Reluctance to perform the procedure is among others due to a lack of standards and guidelines to minimize the risk of complications, such as post-LP head-ache or back pain.

Methods: We provide consensus guidelines for the LP procedure to minimize the risk of complications. The recommendations are based on (1) data from a large multicenter LP feasibility study (evidence level II-2), (2) systematic literature review on LP needle characteristics and post-LP complications (evidence level II-2), (3) discussion of best practice within the Joint Programme Neurodegenerative Disease Research Biomarkers for Alzheimer's disease and Parkinson's Disease and Biomarkers for Multiple Sclerosis consortia (evidence level III).

Results: Our consensus guidelines address contraindications, as well as patient-related and procedure-related risk factors that can influence the development of post-LP complications.

Discussion: When an LP is performed correctly, the procedure is well tolerated and accepted with a low complication rate.

© 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).

Keywords: Lumbar puncture; Cerebrospinal fluid; Post-LP complications; Headache; Back pain; Consensus guidelines; Evidence-based guidelines

1. Introduction

Lumbar puncture (LP) is a technique to sample cerebrospinal fluid (CSF) as a window into brain pathology (Supplemental Data). The procedure involves introducing a needle into the subarachnoid space of the lumbar sac, at a level safely below the spinal cord [1]. Despite modern neuroimaging techniques, LP remains an important diagnostic tool as CSF analysis provides important diagnostic information for many neurological conditions. For example, no procedure can replace the CSF analysis in differential diagnosis of infectious disorders of the central nervous system (e.g., bacterial or viral meningitis, neuroborreliosis). Moreover, CSF analysis is now at the core of the diagnostic criteria for the diagnosis of Alzheimer's disease [2-4]. In addition, an LP is the easiest procedure to perform a CSF pressure measurement. Given the use of CSF analysis for diagnosis, LPs are currently often performed to perform research to discover novel diagnostic biomarkers and understand brain pathology.

A recent large international, multicenter study on LP feasibility that included 3868 patients in a memory clinic setting showed that LPs can be safely performed [5]. The

acceptance rate of an LP was high, especially taking into consideration that there was no acute medical indication.

The most common complications of LP consist of post-LP back pain and post-LP headache (PLPH) [6]. PLPH typically begins within three days after the procedure in most patients [7]. If a patient develops typical PLPH, bed rest, adequate hydration, and simple analgesics should be started [8]. Further review of possible treatments will be given in later sections of this study.

Very rare (prevalence of <0.01%) but potential serious complications consist of post-LP infections, spinal and subdural cerebral hematoma, and cerebral venous thrombosis [1]. In the multicenter LP feasibility study, a substantial proportion (31%) of patients reported post-LP complaints; however, these were mostly mild in nature, and severe complications were very rare [5]. Back pain, headache, and typical PLPH were reported by 17%, 19%, and 9%, respectively [5]. Only 0.3% of the patients needed a blood patch, and in 0.7%, a hospitalization was required [5]. The most important risk factors for post-LP complaints were related to patient characteristics: history of headache and fear of complications. Download English Version:

https://daneshyari.com/en/article/8680345

Download Persian Version:

https://daneshyari.com/article/8680345

Daneshyari.com